The North America Bovine Respiratory Disease Treatment Market was estimated at USD 16.94 million in 2022. It is further projected to reach USD 39.25 million by 2027, growing at a CAGR of 18.3% during the forecast period. The U.S. feedlot industry estimates a huge annual loss for bovine respiratory disease (BRD) due to loss of production, increased labor expenses, pharmaceutical costs, and death deriving from BRD.
BRD refers to any disease of the lower or upper respiratory tracts in cattle and is commonly associated with lung infections, which can cause pneumonia. Bovine Respiratory Disease is far too common, far too costly, and, for the most part, seems far too hard to handle. If cattle are treated more than once, they never get back to that peak performance.
The disease is caused by various factors such as Host factors, which include animal age, immunity, genetics, and exposure to pathogens; environmental factors involve crowding, temperature, commingling and transport, Internal or external parasite infections, and Infectious agents. The weight loss that animal has due to BRD sickness will stay with them throughout the feeding period. Hence, productivity is reduced. Antibiotics and anti-inflammatory drugs are now being used for combination treatment and are expected to improve the treatment's success rate.
This research report segmented and sub-segmented the North America Bovine Respiratory Disease Treatment Market into the following categories:
By Treatment Type:
By Country:
Some of the promising companies operating in the North American Bovine Respiratory Disease Treatment Market are Zoetis Inc., Merck & Co. Inc., Bayer Corporation, Eli Lilly & Co, Merial S.A.S, Boehringer Ingelheim Vetmedica, Novartis Animal Health, Vibrac S.A., Ceva Sante Animale, and Vétoquinol S.A.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Type of Treatment
5.1.1 Anti-Infectious Agents
5.1.1.1 Antibiotics
5.1.1.2 Sulfas
5.1.2 Anti-Parasiticides
5.1.3 Bronchodilators
5.1.4 Oral Rehydration Fluids
5.1.5 Non-Steroidal Anti-Inflammatories
5.1.6 Mucolytics
6. Geographical Analysis
6.1 Introduction
6.2 United States
6.3 Canada
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Zoetis Inc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Merck & Co. Inc.
8.3 Bayer Corporation
8.4 Eli Lilly & Co.
8.5 Merial S.A.S
8.6 Boehringer Ingelheim Vetmedica
8.7 Novartis Animal Health
8.8 Vibrac S.A
8.9 Ceva Sante Animale
8.10 Vétoquinol S.A.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Talk to our analyst and get customised report done according to your research needs
Check if you can avail any discount. Submit your details and our team will get back to you.
Request to avail a free sample report that reflects this market and its growth.